Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN | MicrobiomeTrials← Back to trialsNCT06994845
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2025-11-27Est. Completion: 2030-06-28
Enrollment target: 31 participants Locations- Valley Childrens Hospital, Madera, California, United States
- Childrens Hospital Colorado, Aurora, Colorado, United States
- Univ of Florida Shands Division, Gainesville, Florida, United States
- Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Prim Childrens Hosp Inv Pharm, Salt Lake City, Utah, United States
- Novartis Investigative Site, Córdoba, Córdoba Province, Argentina
- Novartis Investigative Site, Brisbane, Queensland, Australia
- Novartis Investigative Site, Nedlands, Western Australia, Australia
- Novartis Investigative Site, Hangzhou, Zhejiang, China
- Novartis Investigative Site, Beijing, China
- Novartis Investigative Site, Hong Kong, Hong Kong
- Novartis Investigative Site, Beersheba, Israel
- Novartis Investigative Site, Haifa, Israel
- Novartis Investigative Site, Jerusalem, Israel
- Novartis Investigative Site, Petah Tikva, Israel
- Novartis Investigative Site, Toyoake, Aichi-ken, Japan
- Novartis Investigative Site, Kurume, Fukuoka, Japan
Other microbiome trials you might be interested in
Immunoglobulin A (IgA) Nephropathy
The purpose of the study is to evaluate safety, tolerability, and preliminary effectiveness following administration of …
Miami, United StatesEst. completion Sep 2028
IgA Nephropathy (IgAN)C3 GlomerulopathyIC-MPGN
This study looks at how well and safely SGB-9768 works for patients with certain kidney diseases: primary IgA nephropath…
Beijing, ChinaEst. completion Dec 29, 2026
Novartis Investigative Site, Ōtsu, Shiga, JapanNovartis Investigative Site, Fuchū, Tokyo, JapanNovartis Investigative Site, Riyadh, Saudi Arabia